Annexon Competitors

Annexon (NASDAQ:ANNX) and Taro Pharmaceutical Industries (NYSE:TARO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk and profitability.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Annexon and Taro Pharmaceutical Industries, as provided by MarketBeat.com.

Annexon presently has a consensus target price of $34.3333, suggesting a potential upside of 85.79%. Taro Pharmaceutical Industries has a consensus target price of $81.00, suggesting a potential upside of 10.05%. Given Annexon's higher probable upside, research analysts plainly believe Annexon is more favorable than Taro Pharmaceutical Industries.

Valuation & Earnings

This table compares Annexon and Taro Pharmaceutical Industries' revenue, earnings per share and valuation.

Taro Pharmaceutical Industries has higher revenue and earnings than Annexon.

Profitability

This table compares Annexon and Taro Pharmaceutical Industries' net margins, return on equity and return on assets.

Institutional & Insider Ownership

91.2% of Annexon shares are held by institutional investors. Comparatively, 11.2% of Taro Pharmaceutical Industries shares are held by institutional investors. 13.8% of Taro Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Taro Pharmaceutical Industries beats Annexon on 5 of the 9 factors compared between the two stocks.

PTC Therapeutics (NASDAQ:PTCT) and Annexon (NASDAQ:ANNX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Institutional and Insider Ownership

91.2% of Annexon shares are held by institutional investors. 7.0% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares PTC Therapeutics and Annexon's revenue, earnings per share and valuation.

Annexon has lower revenue, but higher earnings than PTC Therapeutics.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for PTC Therapeutics and Annexon, as provided by MarketBeat.

PTC Therapeutics currently has a consensus target price of $65.10, suggesting a potential upside of 67.35%. Annexon has a consensus target price of $34.3333, suggesting a potential upside of 85.79%. Given Annexon's stronger consensus rating and higher probable upside, analysts clearly believe Annexon is more favorable than PTC Therapeutics.

Profitability

This table compares PTC Therapeutics and Annexon's net margins, return on equity and return on assets.

Insmed (NASDAQ:INSM) and Annexon (NASDAQ:ANNX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Insider & Institutional Ownership

91.2% of Annexon shares are owned by institutional investors. 4.6% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Insmed and Annexon's revenue, earnings per share and valuation.

Annexon has lower revenue, but higher earnings than Insmed.

Analyst Ratings

This is a summary of recent recommendations for Insmed and Annexon, as provided by MarketBeat.

Insmed currently has a consensus target price of $53.5714, suggesting a potential upside of 106.12%. Annexon has a consensus target price of $34.3333, suggesting a potential upside of 85.79%. Given Insmed's higher probable upside, equities research analysts clearly believe Insmed is more favorable than Annexon.

Profitability

This table compares Insmed and Annexon's net margins, return on equity and return on assets.

Summary

Insmed beats Annexon on 6 of the 9 factors compared between the two stocks.

Pacira BioSciences (NASDAQ:PCRX) and Annexon (NASDAQ:ANNX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Insider & Institutional Ownership

91.2% of Annexon shares are owned by institutional investors. 5.8% of Pacira BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Pacira BioSciences and Annexon's revenue, earnings per share and valuation.

Pacira BioSciences has higher revenue and earnings than Annexon.

Analyst Ratings

This is a summary of recent recommendations for Pacira BioSciences and Annexon, as provided by MarketBeat.

Pacira BioSciences currently has a consensus target price of $78.5833, suggesting a potential upside of 29.06%. Annexon has a consensus target price of $34.3333, suggesting a potential upside of 85.79%. Given Annexon's stronger consensus rating and higher probable upside, analysts clearly believe Annexon is more favorable than Pacira BioSciences.

Profitability

This table compares Pacira BioSciences and Annexon's net margins, return on equity and return on assets.

Summary

Pacira BioSciences beats Annexon on 7 of the 10 factors compared between the two stocks.

Rocket Pharmaceuticals (NASDAQ:RCKT) and Annexon (NASDAQ:ANNX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Rocket Pharmaceuticals and Annexon, as provided by MarketBeat.

Rocket Pharmaceuticals currently has a consensus target price of $59.1818, suggesting a potential upside of 36.52%. Annexon has a consensus target price of $34.3333, suggesting a potential upside of 85.79%. Given Annexon's stronger consensus rating and higher probable upside, analysts clearly believe Annexon is more favorable than Rocket Pharmaceuticals.

Profitability

This table compares Rocket Pharmaceuticals and Annexon's net margins, return on equity and return on assets.

Insider & Institutional Ownership

91.2% of Annexon shares are owned by institutional investors. 41.4% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Rocket Pharmaceuticals and Annexon's revenue, earnings per share and valuation.

Annexon (NASDAQ:ANNX) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for Annexon and MorphoSys, as reported by MarketBeat.

Annexon currently has a consensus price target of $34.3333, suggesting a potential upside of 85.79%. Given Annexon's stronger consensus rating and higher probable upside, analysts plainly believe Annexon is more favorable than MorphoSys.

Profitability

This table compares Annexon and MorphoSys' net margins, return on equity and return on assets.

Institutional & Insider Ownership

91.2% of Annexon shares are owned by institutional investors. Comparatively, 3.1% of MorphoSys shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Annexon and MorphoSys' top-line revenue, earnings per share (EPS) and valuation.

Annexon has higher earnings, but lower revenue than MorphoSys.

Summary

Annexon beats MorphoSys on 5 of the 9 factors compared between the two stocks.